GlassScriptPhysician profile
Thomas Robert Liebermann
NPI 1285602342
$556.39
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $101.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $165.49 | 2019-2020 | |
| Abbvie INC. | $84.65 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.51 | 2019-2020 | |
| Gilead Sciences, INC. | $47.21 | 2019 | |
| Janssen Biotech, INC. | $44.51 | 2019 | |
| Daiichi Sankyo INC. | $42.28 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $23.75 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $14.44 | 2019 | |
| Merck Sharp & Dohme LLC | $14.38 | 2019 | |
| Alfasigma USA, INC. | $13.11 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.72 | 2019 | |
| Pfizer INC. | $12.34 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Liebermann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.